Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
BOSTON, Mass. | June 23, 2026 Mediar Therapeutics has announced that the first cohorts have been dosed in its...
